Chronic Low Back Pain Clinical Trial
Official title:
A Randomized Sham-Controlled Clinical Study to Evaluate the Effects of the Magnetic Molecular Energizer (MME)on Chronic Low Back Pain
The purpose of this study is to test whether or not the Magnetic Molecular Energizer (MME) device provides a well tolerated and effective intervention to reduce pain, pain-related symptoms and improve ability to function in those diagnosed with the condition “Chronic Low Back Pain” (chronic LBP).
Pilot studies conducted by AMRI International suggest that 0.5T static magnetic field energy
as supplied by the investigational device Magnetic Molecular Energizer (MME) may be
effective for relieving chronic low back pain that has been persistent despite conventional
therapy. This study is is a randomized, sham-controlled trial intended to show whether or
not the MME intervention is an effective, well tolerated intervention for the reduction of
pain, pain related symptoms and improved ability to function in those diagnosed with the
condition, chronic low back pain.
The MME procedure consists of laying on a treatment bed with the individual's body
positioned between two large, electromagnetic coils that create a very strong (0.3T - 0.5T)
magnetic field that passes through the body. The device bears a superficial resemblance to
an open MRI machine. The field is focused on the low back area. The total intervention time
for the study is 140 hr of MME exposure, consisting of 8 - 12 hrs per day for 12 - 18
consecutive days or nights. Participants with be assessed prior to starting the intervention
by history and physical exam conducted by one of the physician investigators, assessing pain
level by using a visual analogue pain scale, assessing functional ability using the Oswestry
Low Back Pain Disability Index questionnaire and assessment of cutaneous perception
threshold (CPT) using the Neurometer device.
Pain scale levels will be assessed daily throughout the intervention period. At the
conclusion of the intervention period, CPT testing will be repeated. One month after the
intervention, the Oswestry Low Back Pain Disability Index questionnaire will be mailed to
the participant. The final evaluation will be six months after the intervention. The
participant is to return to the clinic and repeat CPT testing, report pain levels and
complete the Oswestry Low Back Pain Disability Index questionnaire.
The targeted enrollment for the trial is 100 participants. The participants will be
randomized so that 50 receive the active procedure and 50 will receive a sham procedure. The
sham procedure is provided by a MME device that has been disabled so that the machine
appears to turn on, but no magnetic field is produced. When the final post-intervention
follow-up has been completed the participants will be informed whether they received the
active or sham procedure. Those who received the sham procedure will be offered to receive
the active procedure if they desire. The same evaluations will be repeated with this
cross-over group, but the data will be reported separately from the main trial results.
Participants are not asked to discontinue their usual medications or treatments for their
low back pain. Medication usage will be assessed to see if there is any change in usage
pattern associated with the procedure.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03243084 -
Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Completed |
NCT03162952 -
RAND Center of Excellence for the Study of Appropriateness of Care in CAM
|
||
Completed |
NCT03240146 -
Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain
|
N/A | |
Completed |
NCT05282589 -
Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients
|
N/A | |
Completed |
NCT03637998 -
Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain
|
N/A | |
Recruiting |
NCT02289170 -
Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)
|
N/A | |
Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
Completed |
NCT02231554 -
Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT02063503 -
Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients
|
N/A | |
Terminated |
NCT01620775 -
MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain
|
N/A | |
Completed |
NCT01704677 -
Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up
|
N/A | |
Completed |
NCT01177280 -
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes
|
N/A | |
Completed |
NCT01177241 -
Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids
|
N/A | |
Completed |
NCT01490905 -
A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain
|
Phase 4 | |
Completed |
NCT01177254 -
Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions
|
N/A | |
Completed |
NCT00984815 -
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
|
Phase 3 | |
Completed |
NCT00763321 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 | |
Completed |
NCT00767806 -
A Study for Patient With Chronic Low Back Pain
|
Phase 3 | |
Completed |
NCT00761150 -
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
|
Phase 3 |